Christopher Porter

Christopher Porter is the Sir John Monash Distinguished Professor and Director of the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University. He holds fellowships with the American Association of Pharmaceutical Scientists and the Royal Australian Chemical Institute. His research focuses on drug delivery systems, lymphatic transport, and nanomedicines, with significant contributions to lipid-based formulations and dendrimer technologies. Key achievements include the Glyph® lymphatic targeting platform (Phase 2 clinical trial) and the DEP® dendrimer system (Phase 2 clinical trial).

• Education: Undergraduate and graduate studies at the University of Nottingham.
• Key Awards: Clarivate Highly Cited Researcher (2015–2024), APSA Medal (2017), Honorary Doctorate (Uppsala University, 2018).

Research interests span oral bioavailability enhancement, lipid-modified drug systems, and translational drug delivery. His work has generated over $30M in funding and 15+ patent families. Notable collaborations include PureTech Health/Seaport Therapeutics and Starpharma.